Remove 2021 Remove Medical Records Remove Pharmaceutical Companies
article thumbnail

STAT+: Truveta enlists health systems, drugmakers to launch ambitious new genomic database

STAT

The genetic data, cross-referenced with the patients’ de-identified medical records, will be available for purchase for researchers and life sciences companies. Pharmaceutical company Regeneron has invested $119.5 Pharmaceutical company Regeneron has invested $119.5

article thumbnail

NHS patient data upload delayed by two months, says UK

pharmaphorum

The centralised database of medical records from 55 million people was due to come online on 1 July, but the start date has now been pushed back to 1 September, according to Minister for Public Health, Primary Care & Prevention Jo Churchill. — Rachel Clarke (@doctor_oxford) June 8, 2021.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

As Apple Rolls Out Medication Tracking to all iPhones, Pharma Must Embrace Connectivity

pharmaphorum

You wave your iPhone over a digital kiosk, instantly uploading your current medical record and insurance information. As a result, pharmaceutical companies are still licking their wounds from their attempts to compete for patients’ attention with the likes of Instagram and Facebook. We take Apple Health here.”

article thumbnail

The Use of Artificial Intelligence in the Pharmaceutical Industry

Viseven

According to The McKinsey Global Institute’s research , the influence of AI and machine learning on the pharma market generated around $100B across the US healthcare system in 2021. Here, we are diving deep into the main aspects of AI influence. Manufacturing process. Clinical Trials.

article thumbnail

Adherence to NICE criteria for initiation and continuation of treatment with a biologic in atopic dermatitis

Hospital Pharmacy Europe

A patient access scheme or commercial arrangement associated with the NICE guidance is a way for pharmaceutical companies to lower the acquisition cost to the NHS to improve its cost-effectiveness, so enabling patients to gain access to high-cost medicine treatments. TA681, March 2021. J Skin Sex Transm Dis 2021;3:151–5.